diabetes patient News
-
First patient treated in TIKOMED’s Phase II study of clinical islet transplantation in patients with brittle diabetes
TIKOMED, a specialty pharmaceutical company developing an infusion product for improving the outcome in cell therapies, today announced that the first patient has been treated in TIKOMED’s ongoing Phase II international, multicenter study – NNCIT-02. In the NNCIT-02 study, brittle diabetes patients being transplanted with islets of Langerhans are treated with IBSOLVMIR® which has ...
By TIKOMED AB
-
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the first patient has been treated in its Phase 1b open-label, proof-of-concept study of ...
-
Medis QFR continues to show superiority over standard angiography, after a FU-period of 2 years
In the September 2022 issue of JACC journals (https://www.jacc.org/doi/10.1016/j.jacc.2022.06.044), the FAVOR III China Study Group published a sub-study that was aimed to ascertain whether the beneficial outcomes of QFR® guidance for lesion selection during PCI is affected by diabetes status. From the total of 3825 patients enrolled, 1295 (33.9%) had diabetes. The study confirmed that the ...
-
Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes ...
-
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when ...
-
Top 5 Israeli innovations of the past decade
The Start-up Nation has made several ground breaking discoveries in the fields of technology, science, and innovation during the past decade.The first artificial pancreas – A potential cure for diabetes? In a possible future cure for diabetes, researchers at Betalin Therapeutics have engineered the first artificial pancreas. It can be inserted underneath the skin, without anesthesia and ...
-
Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin injections. The study sponsors used participant data to ...
By Longenesis
-
BioXtreme and Advanced Medical Solutions s.r.o sign cooperation agreement in Czech Republic and Slovakia
BioXtreme is proud to announce a new cooperation agreement was recently signed with Advanced Medical Solutions s.r.o (AMS) from Brno, Czech Republic. The agreement situates AMS as BioXtreme’s representative in the Czech Republic and Slovakia, with exclusive distribution rights for BioXtreme’s neurorehabilitation products and forming connections with hospitals and rehabilitation ...
-
Impact of antidiabetic treatments must be taken into account in studying the gut microbiota
Research on gut microbiota (bacteria of the digestive tract) has for some years greatly contributed to advancing medical science. Within an international consortium, INRA scientists along with foreign colleagues have shown the impact of the antidiabetic treatment metformin on the gut microbiota of Type 2 Diabetes patients (T2D). The results, published in Nature on December 2, stress that the ...
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
Microlyte SURGICAL Associated with Positive Outcomes in Prospective Clinical Case Series in Patients at Risk for Surgical Site Infection
Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection. Results will be published in the October ...
-
Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment
Hitachi, Ltd. (TSE: 6501, Hitachi), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood ...
-
AOTI Receives China FDA Approval for Topical Wound Oxygen (TWO2) Therapy Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have ...
-
Research Finds Nearly 40% of Diabetes Patients who Suffer a Lower Extremity Amputation Endure Another Within Five Years
Reamputation Rates Have Not Improved Over Two Decades. SOMERVILLE, Mass., June 10, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which found patients with diabetes who have an amputation have a 37 percent chance of having reamputation within five years. The ...
-
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the Company in 2014, is a monumental milestone for ...
-
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the ...
-
Notitia Biotechnologies company announces expansion of study population for Covid-19 phase 2 study (COVGUT20) for NBT-NM108
After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients. "Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to ...
-
Notitia Biotechnologies receives approval from FDA for phase 2A clinical trial in diabetic & prediabetic patients
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a ...
-
Smart Home Lab - a Helpful Alternative to a Physician’s Office
What if the laboratory came home to you? Latest since the corona pandemic, the subject of “selftests” and “rapid tests” has finally reached a broad public. While previously it was more of a topic for chronic patients (e.g. diabetics) or for occasional tests (e.g. pregnancy test), we now see a clear trend. The determination of own body values, disease ...
-
Notitia Biotechnologies Develops Revolutionary Foundation Guild Lbp for Patients With Diabetic Kidney Disease (DKD)
Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format. Notitia is preparing the Investigational New Drug (IND) ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you